Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910180 | 0.86 | MEN1 (0.48) | MEN1KMT2AOPRM1OPRD1RAB9A | |
| SCHEMBL10305062 | 0.84 | RAB9A (0.41) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL6840494 | 0.81 | RAB9A (0.43) | MEN1KMT2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL14547221 | 0.77 | RAB9A (0.40) | MEN1KMT2AOPRM1OPRD1RAB9A | |
| SCHEMBL12788604 | 0.77 | MEN1 (0.42) | MEN1KMT2AOPRM1OPRD1RAB9A | |
| SCHEMBL14195506 | 0.77 | RIPK1 (0.42) | MEN1KMT2AOPRM1OPRD1RAB9A | |
| SCHEMBL9512579 | 0.76 | EGFR (0.42) | MEN1KMT2AOPRM1OPRD1RAB9A | |
| SCHEMBL1135252 | 0.74 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL3508756 | 0.74 | MEN1 (0.49) | MEN1KMT2AALDH1A1KDM4EOPRM1 | |
| SCHEMBL20890507 | 0.74 | CHRNB2 (0.44) | CYP1A2CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MEN1 4515/4885KMT2A 4151/4885ALDH1A1 2920/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | MEN1 4515/4885KMT2A 4151/4885ALDH1A1 2920/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MEN1 4515/4885KMT2A 4151/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.